A new simple-to-use reconstitution device for C1 Esterase Inhibitor [Human] (Cinryze) has been introduced by ViroPharma.

The reconstitution system combines Cinryze and West Pharmaceutical Services’s Mix2Vial needleless reconstitution system.

Cinryze has been approved by the FDA for routine prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE).

The Mix2Vial transfer device offers an asymmetrical vial skirt to help achieve new levels of simplicity in reconstituting Cinryze.

Cinryze can be administered as a dose of 1,000 units for every three or four days or at an injection rate of 1ml per minute for routine prophylaxis against angioedema attacks in HAE patients.

After receiving Cinryze, the most common adverse reactions observed by greater than or equal to 5% of the 24 evaluable subjects were upper respiratory tract infections, sinusitis, rashes and headaches, trials revealed.

Mix2Vial, in combination with Cinryze, offers patients, care givers and physicians a needleless system to encourage independence and simplify the reconstitution process.